Hólyagrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

2077 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution 2 000 000 EUR· until 2030. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Görögország· EU contribution 197 264 EUR· until 2027. márc.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Írország· EU contribution 328 495 EUR· until 2028. aug.· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Írország· EU contribution 13 615 935 EUR· until 2029. dec.· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Izrael· EU contribution 2 498 731 EUR· until 2026. nov.

5 of 9 running projects, newest first. Listed amounts together: 36,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

  NCT07185945· Guru Sonpavde· Frissítve: 2026. nov. 9.

  “Funder withdrew”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 5.

  “\< 75 % participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

  NCT06571708· Columbia University· Frissítve: 2026. nov. 3.

  “Change in standard of care treatment for muscle-invasive bladder cancer”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Frissítve: 2026. okt. 29.

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Frissítve: 2026. okt. 23.

  “The trial was prematurely terminated due to the sponsor's decision.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Evaluation of Naloxegol in the Prevention of POI After Cystectomy

  NCT04219046· Institut Paoli-Calmettes· Frissítve: 2026. okt. 14.

  “the industrial partner withdrew from the study”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

  NCT06373419· Thunder Bay Regional Health Research Institute· Frissítve: 2026. okt. 1.

  “Lack of enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

  NCT06290687· Case Comprehensive Cancer Center· Frissítve: 2026. szept. 24.

  “PI left institution”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Frissítve: 2026. szept. 22.

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

  NCT07414992· Memorial Sloan Kettering Cancer Center· Frissítve: 2026. szept. 3.

  “The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

  NCT03775265· National Cancer Institute (NCI)· Forrás

• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

  NCT07475806· Astellas Pharma Global Development, Inc.· Forrás

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

  NCT03854474· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT04164082· National Cancer Institute (NCI)· Forrás

• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

  NCT06228066· National Cancer Institute (NCI)· Forrás

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Forrás

• A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· National Cancer Institute (NCI)· Forrás

• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

  NCT04579224· National Cancer Institute (NCI)· Forrás

• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

  NCT04963153· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 77
• Genome-Wide Association Study 18

• Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review.

  Curr Urol Rep, 2026. okt.

• BCG vaccination mitigates tau pathology and restores cognitive function in PS19 mice.

  Sci Adv, 2026. okt.

• Imaging in Upper Tract Urothelial Carcinoma: Diagnostic Accuracy of Current Modalities for Local Tumor Staging.

  Curr Urol Rep, 2026. okt.

• Metastatic muscle invasive bladder cancer in pregnancy.

  BMJ Case Rep, 2026. szept.

• Age as a pre-operative predictor of uterine, bladder, and intestinal invasion in cervical cancer.

  Acta Radiol, 2026. szept.

• MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.

  Nat Commun, 2026. aug.

• Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.

  BJU Int, 2026. aug.

• Development and validation of a preoperative biparametric MRI-based habitat model for risk stratification of non-muscle-invasive bladder cancer.

  BMC Med Imaging, 2026. aug.

• VI-RADS and beyond in bladder MRI: a pictorial review of quality control, response assessment, and artificial intelligence.

  Eur J Radiol, 2026. júl.

• VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification.

  Eur Urol Oncol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.